Measurement of costs and scales for outcome evaluation in health economic studies of Parkinson's disease

Movement Disorders

Volumn 29, Issue 2, 2014, Pages 169-176

  Dodel, Richard ^a   Jönsson, Bengt ^b   Reese, Jens Peter ^a   Winter, Yaroslav ^a   Martinez Martin, Pablo ^c   Holloway, Robert ^d   Sampaio, Cristina ^e   Růžička, Evžen ^f   Hawthorne, Graeme ^g   Oertel, Wolfgang ^a   Poewe, Werner ^h   Stebbins, Glenn ⁱ   Rascol, Oliver ^j   Goetz, Christopher G ⁱ   Schrag, Anette ^k  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b STOCKHOLM SCHOOL OF ECONOMICS   (Sweden)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^e INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^f CHARLES UNIVERSITY   (Czech Republic)

^g UNIVERSITY OF MELBOURNE   (Australia)

^h INNSBRUCK MEDICAL UNIVERSITY   (Austria)

ⁱ RUSH UNIVERSITY MEDICAL CENTER   (United States)

^j Laboratoire de Pharmacologie Medicale et Clinique   (France)

^k UNIVERSITY COLLEGE LONDON   (United Kingdom)

more..

Author keywords

Cost; Cost effectiveness; Cost utility; Health economics; Parkinson's disease

Indexed keywords

COST; COST EFFECTIVENESS; COST UTILITY; HEALTH ECONOMICS; PARKINSON'S DISEASE;

COST OF ILLNESS; COST-BENEFIT ANALYSIS; HUMANS; PARKINSON DISEASE; PSYCHOMETRICS;

EID: 84894287908     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25571     Document Type: Review

References (99)

1. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
2. Bach JP, Ziegler U, Deuschl G, Dodel R. Projected numbers of people with movement disorders in the years 2030 and 2050. Mov Disord 2011;26:2286-2290.
3. Dorsey ER, Constantinescu R, Thompson JP, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007;68:384-386.
4. Drummond MF, Sculpher MJ, Torrance GW, O'Brien B, Stoddart GL. Methods for the Economic Evaluation of Healthcare Programmes. Oxford, United Kingdom: Oxford University Press; 2005.
5. Weinstein MC. Recent developments in decision-analytic modelling for economic evaluation. Pharmacoeconomics 2006;24:1043-1053.
6. Dams J, Conrads-Frank A, Reese JP, Bornschein B, Siebert U, Dodel R. Modelling the cost effectiveness of treatments for Parkinson's disease: a methodological review. Pharmacoeconomics 2011;29:1025-1049.
7. Shearer J, Green C, Counsell CE, Zajicek JP. The use of decision-analytic models in Parkinson's disease: a systematic review and critical appraisal. Appl Health Econ Health Policy 2011;9:243-258.
8. Siebert U, Bornschein B, Walbert T, Dodel RC. Systematic assessment of decision models in Parkinson's disease. Value Health 2004;7:610-626.
9. Schrag A, Barone P, Brown RG, et al. Depression rating scales in Parkinson's disease: critique and recommendations. Mov Disord 2007;22:1077-1092.
10. Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008;23:2129-2170.
11. The Netherlands Cancer Institute. Assessing health status and quality-of-life instruments: attributes and review criteria. Qual Life Res 2002;11:193-205.
12. Terwee CB, Bot SD, de Boer MR, et al. Quality criteria were proposed for measurement properties of health status questionnaires. J Clin Epidemiol 2007;60:34-42.
13. Strzelczyk A, Reese JP, Dodel R, Hamer HM. Cost of epilepsy: a systematic review. Pharmacoeconomics 2008;26:463-476.
14. von Campenhausen S, Winter Y, Silva AR, et al. Costs of illness and care in Parkinson's Disease: an evaluation in six countries. Eur Neuropsychopharmacol 2011;21:180-191.
15. Vossius C, Gjerstad M, Baas H, Larsen JP. Drug costs for patients with Parkinson's disease in two different European countries. Acta Neurol Scand 2006;113:228-232.
16. Lopez-Bastida J, Oliva J, Antonanzas F, et al. Spanish recommendations on economic evaluation of health technologies. Eur J Health Econ 2010;11:513-520.
17. Walter E, Zehetmayr S. Guidelines for health-economic evaluations in Austria. Wien Med Wochenschr 2006;156(23-24):628-632.
18. Goetghebeur MM, Rindress D. Towards a European consensus on conducting and reporting health economic evaluations-a report from the ISPOR Inaugural European Conference. Value Health 1999;2:281-287.
19. Schoffski O, Schulenburg J. Consensus on a framework for European guidelines-declaration of the EUROMET Group. In: Schoffski O, Schulenburg J, eds. Gesundheitsokonomische Evaluationen. Berlin, Germany: Springer; 2007:485-489.
20. Dodel RC, Singer M, Kohne-Volland R, et al. The economic impact of Parkinson's disease: an estimation based on a 3-month prospective analysis. Pharmacoeconomics 1998;14:299-312.
21. Barth F, Baum B, Bremen D, Meuser T, Jost WH. Indirect costs in idiopathic Parkinson's disease. Fortschr Neurol Psychiatr 2005;73:187-191.
22. Cubo E, Martinez Martin P, Gonzalez M, Frades B. Impact of motor and non-motor symptoms on the direct costs of Parkinson's disease. Neurologia 2009;24:15-23.
23. Dengler I, Leukel N, Meuser T, Jost WH. Prospektive Erfassung der direkten und indirekten Kosten des idiopathischen Parkinson-Syndroms. Nervenarzt 2006;77:1204-1209.
24. Ehret R, Balzer-Geldsetzer M, Reese JP, et al. Direct costs for Parkinson's treatment in private neurology practices in Berlin. Nervenarzt 2009;80:452-458.
25. Findley L, Aujla M, Bain PG, et al. Direct economic impact of Parkinson's disease: a research survey in the United Kingdom. Mov Disord 2003;18:1139-1145.
26. Huse DM, Schulman K, Orsini L, Castelli-Haley J, Kennedy S, Lenhart G. Burden of illness in Parkinson's disease. Mov Disord 2005;20:1449-1454.
27. Guttman M, Slaughter PM, Theriault ME, DeBoer DP, Naylor CD. Burden of parkinsonism: a population-based study. Mov Disord 2003;18:313-336.
28. Hagell P, Nordling S, Reimer J, Grabowski M, Persson U. Resource use and costs in a Swedish cohort of patients with Parkinson's disease. Mov Disord 2002;17:1213-1220.
29. Keranen T, Kaakkola S, Sotaniemi K. Economic burden and quality of life impairment increase with severity of PD. Parkinsonism Relat Disord 2003;9:163-168.
30. Leibson CL, Long KH, Maraganore DM, et al. Direct medical costs associated with Parkinson's disease: a population-based study. Mov Disord 2006;21:1864-1871.
31. LePen C, Wait S, Moutard-Martin F, Dujardin M, Ziegler M. Cost of illness and disease severity in a cohort of French patients with Parkinson's disease. Pharmacoeconomics 1999;16:59-69.
32. McCrone P, Allcock LM, Burn DJ. Predicting the cost of Parkinson's disease. Mov Disord 2007;22:804-812.
33. Noyes K, Liu H, Li Y, Holloway R, Dick AW. Economic burden associated with Parkinson's disease on elderly Medicare beneficiaries. Mov Disord 2006;21:362-372.
34. Ragothaman M, Govindappa ST, Rattihalli R, Subbakrishna DK, Muthane UB. Direct costs of managing Parkinson's disease in India: concerns in a developing country. Mov Disord 2006;21:1755-1758.
35. Reese JP, Winter Y, Balzer-Geldsetzer M, et al. Parkinson's disease: cost-of-illness in an outpatient cohort. Gesundheitswesen 2010;73:22-29.
36. von Campenhausen S, Winter Y, Gasser J, et al. Cost of illness and health services patterns in Morbus Parkinson in Austria. Wien Klin Wochenschr 2009;121(17-18):574-582.
37. Wang G, Cheng Q, Zheng R, et al. Economic burden of Parkinson's disease in a developing country: a retrospective cost analysis in Shanghai, China. Mov Disord 2006;21:1439-1443.
38. Winter Y, Balzer-Geldsetzer M, Spottke A, et al. Longitudinal study of the socioeconomic burden of Parkinson's disease in Germany. Eur J Neurol 2010;17:1156-1163.
39. Winter Y, von Campenhausen S, Brozova H, et al. Costs of Parkinson's disease in eastern Europe: a Czech cohort study. Parkinsonism Relat Disord 2010;16:51-56.
40. Winter Y, von Campenhausen S, Gasser J, et al. Social and clinical determinants of quality of life in Parkinson's disease in Austria: a cohort study. J Neurol 2010;257:638-645.
41. Winter Y, von Campenhausen S, Popov G, et al. Costs of illness in a Russian cohort of patients with Parkinson's disease. Pharmacoeconomics 2009;27:571-584.
42. Winter Y, von Campenhausen S, Reese JP, et al. Costs of Parkinson's disease and antiparkinsonian pharmacotherapy: an Italian cohort study. Neurodegener Dis 2010;7:365-372.
43. Martinez-Martin P, Jeukens-Visser M, Lyons KE, et al. Health-related quality-of-life scales in Parkinson's disease: critique and recommendations. Mov Disord 2011;26:2371-2380.
44. Neumann PJ, Goldie SJ, Weinstein MC. Preference-based measures in economic evaluation in health care. Annu Rev Public Health 2000;21:587-611.
45. Hawthorne G, Richardson J. Measuring the value of program outcomes: a review of multiattribute utility measures. Expert Rev Pharmacoecon Outcomes Res 2001;1:215-228.
46. Froberg DG, Kane RL. Methodology for measuring health-state preferences-I: measurement strategies. J Clin Epidemiol 1989;42:345-354.
47. Froberg DG, Kane RL. Methodology for measuring health-state preferences-II: scaling methods. J Clin Epidemiol 1989;42:459-471.
48. Brazier J, Deverill M, Green C, Harper R, Booth A. A review of the use of health status measures in economic evaluation. Health Technol Assess 1999;3:i-iv, 1-164.
49. Bennett K, Torrance G. Measuring health state preferences and utilities: rating scale, time trade-off, and standard gamble techniques. In: Spilker B, ed. Quality of Life and Pharmacoeconomics in Clinical Trials. Philadelphia: Lippincott-Raven Publishers; 1996:253-265.
50. Torrance GW, Boyle MH, Horwood SP. Application of multi-attribute utility theory to measure social preferences for health states. Oper Res 1982;30:1043-1069.
51. Parkin D, Devlin N. Is there a case for using visual analogue scale valuations in cost-utility analysis? Health Econ 2006;15:653-664.
52. Robinson A, Dolan P, Williams A. Valuing health status using VAS and TTO: what lies behind the numbers? Soc Sci Med 1997;45:1289-1297.
53. Green C, Brazier J, Deverill M. Valuing health-related quality of life. A review of health state valuation techniques. Pharmacoeconomics 2000;17:151-165.
54. Gyrd-Hansen D. Willingness to pay for a QALY: theoretical and methodological issues. Pharmacoeconomics 2005;23:423-432.
55. Palmer CS, Schmier JK, Snyder E, Scott B. Patient preferences and utilities for 'off-time' outcomes in the treatment of Parkinson's disease. Qual Life Res 2000;9:819-827.
56. Gray A, McNamara I, Aziz T, et al. Quality of life outcomes following surgical treatment of Parkinson's disease. Mov Disord 2002;17:68-75.
57. Morimoto T, Shimbo T, Orav JE, et al. Impact of social functioning and vitality on preference for life in patients with Parkinson's disease. Mov Disord 2003;18:171-175.
58. Nemeth G. Health related quality of life outcome instruments. Eur J Spine 2006;15(suppl 1):S44-S51.
59. The EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199-208.
60. A'Campo LE, Spliethoff-Kamminga NG, Macht M, Roos RA. Caregiver education in Parkinson's disease: formative evaluation of a standardized program in seven European countries. Qual Life Res;19:55-64.
61. Cheung YB, Tan LC, Lau PN, Au WL, Luo N. Mapping the eight-item Parkinson's Disease Questionnaire (PDQ-8) to the EQ-5D utility index. Qual Life Res 2008;17:1173-1181.
62. Clarke CE, Furmston A, Morgan E, et al. Pilot randomised controlled trial of occupational therapy to optimise independence in Parkinson's disease: the PD OT trial. J Neurol Neurosurg Psychiatry 2009;80:976-978.
63. Litvinenko IV, Odinak MM, Mogil'naia VI, Sologub OS, Sakharovskaia AA. Direct switch from conventional levodopa to stalevo (levodopa/carbidopa/entacapone) improves quality of life in Parkinson's disease: results of an open-label clinical study. Zh Nevrol Psikhiatr Im S S Korsakova 2009;109:51-54.
64. Luo N, Low S, Lau PN, Au WL, Tan LC. Is EQ-5D a valid quality of life instrument in patients with Parkinson's disease? A study in Singapore. Ann Acad Med Singapore 2009;38:521-528.
65. Noyes K, Dick AW, Holloway RG. Pramipexole versus levodopa in patients with early Parkinson's disease: effect on generic and disease-specific quality of life. Value Health 2006;9:28-38.
66. Noyes K, Dick AW, Holloway RG. The implications of using US-specific EQ-5D preference weights for cost-effectiveness evaluation. Med Decis Making 2007;27:327-334.
67. Reuther M, Spottke EA, Klotsche J, et al. Assessing health-related quality of life in patients with Parkinson's disease in a prospective longitudinal study. Parkinsonism Relat Disord 2007;13:108-114.
68. Schrag A, Jahanshahi M, Quinn N. How does Parkinson's disease affect quality of life? A comparison with quality of life in the general population. Mov Disord 2000;15:1112-1118.
69. Schrag A, Selai C, Jahanshahi M, Quinn NP. The EQ-5D-a generic quality of life measure-is a useful instrument to measure quality of life in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 2000;69:67-73.
70. Schrag A, Spottke A, Quinn NP, Dodel R. Comparative responsiveness of Parkinson's disease scales to change over time. Mov Disord 2009;24:813-818.
71. Siderowf A, Ravina B, Glick HA. Preference-based quality-of-life in patients with Parkinson's disease. Neurology 2002;59:103-108.
72. Siderowf AD, Werner RM. The EQ-5D-a generic quality of life measure-is a useful instrument to measure quality of life in patients with Parkinson's disease [letter]. J Neurol Neurosurg Psychiatry 2001;70:817.
73. Winter Y, von Campenhausen S, Popov G, et al. Social and clinical determinants of quality of life in Parkinson's disease in a Russian cohort study. Parkinsonism Relat Disord 2010;16:243-248.
74. Visser JE, Allum JH, Carpenter MG, et al. Subthalamic nucleus stimulation and levodopa-resistant postural instability in Parkinson's disease. J Neurol 2008;255:205-210.
75. Coons SJ, Rao S, Keininger DL, Hays RD. A comparative review of generic quality of life instruments. Pharmacoeconomics 2000;17:13-35.
76. Petrou S, Hockley C. An investigation into the empirical validity of the EQ-5D and SF-6D based on hypothetical preferences in a general population. Health Econ 2005;14:1169-1189.
77. Naglie G, Tomlinson G, Tansey C, et al. Utility-based Quality of Life measures in Alzheimer's disease. Qual Life Res 2006;15:631-643.
78. Horsman J, Furlong W, Feeny D, Torrance G. The Health Utilities Index (HUI): concepts, measurement properties and applications [serial online]. Health Qual Life Outcomes 2003;1:54.
79. Furlong WJ, Feeny DH, Torrance GW, Barr RD. The Health Utilities Index (HUI) system for assessing health-related quality of life in clinical studies. Ann Med 2001;33:375-384.
80. Kleiner-Fisman G, Stern MB, Fisman DN. Health-related quality of life in Parkinson disease: correlation between Health Utilities Index III and Unified Parkinson's Disease Rating Scale (UPDRS) in U.S. male veterans [serial online]. Health Qual Life Outcomes 2010;8:91.
81. Kristiansen IS, Bingefors K, Nyholm D, Isacson D. Short-term cost and health consequences of duodenal levodopa infusion in advanced Parkinson's disease in Sweden: an exploratory study. Appl Health Econ Health Policy 2009;7:167-180.
82. Nyholm D, Nilsson Remahl AI, Dizdar N, et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 2005;64:216-223.
83. Haapaniemi TH, Sotaniemi KA, Sintonen H, Taimela E. The generic 15D instrument is valid and feasible for measuring health related quality of life in Parkinson's disease. J Neurol Neurosurg Psychiatry 2004;75:976-983.
84. Brazier J, Usherwood T, Harper R, Thomas K. Deriving a preference-based single index from the UK SF-36 Health Survey. J Clin Epidemiol 1998;51:1115-1128.
85. Nichol MB, Sengupta N, Globe DR. Evaluating quality-adjusted life years: estimation of the Health Utility Index (HUI2) from the SF-36. Med Decis Making 2001;21:105-112.
86. Hawthorne G, Densley K, Pallant JF, Mortimer D, Segal L. Deriving utility scores from the SF-36 health instrument using Rasch analysis. Qual Life Res 2008;17:1183-1193.
87. Mortimer D, Segal L, Hawthorne G, Harris A. Item-based versus subscale-based mappings from the SF-36 to a preference-based quality of life measure. Value Health 2007;10:398-407.
88. Vossius C, Nilsen OB, Larsen JP. Health state values during the first year of drug treatment in early-stage Parkinson's disease: a prospective, population-based, cohort study. Drugs Aging 2009;26:973-980.
89. Wimo A, Jonsson L, Zbrozek A. The Resource Utilization in Dementia (RUD) instrument is valid for assessing informal care time in community-living patients with dementia. J Nutr Health Aging 2010;14:685-690.
90. Wimo A, Wetterholm A, Mastey V, et al. Evaluation of the resource utilization and caregiver time in anti-dementia drug trials: a quantitative battery. In: Wimo A, Jonsson B, Karlsson G, eds. The Health Economics of Dementia. London: John Wiley & Sons; 1988:465-499.
91. Guyatt GH, Jaeschke RJ. Reassessing quality-of-life instruments in the evaluation of new drugs. Pharmacoeconomics 1997;12:621-626.
92. Revicki DA, Leidy NK. Integrating patient preferences into health outcomes assessment: the multiattribute Asthma Symptom Utility Index. Chest 1998;114:998-1007.
93. Marra CA, Woolcott JC, Kopec JA, et al. A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis. Soc Sci Med 2005;60:1571-1582.
94. Schoffski O, Schulenburg JM. Gesundheitsokonomische Evaluationen. Berlin, Germany: Springer; 2007.
95. Marras C, Lang A, Krahn M, Tomlinson G, Naglie G. Quality of life in early Parkinson's disease: impact of dyskinesias and motor fluctuations. Mov Disord 2004;19:22-28.
96. Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson's disease? J Neurol Neurosurg Psychiatry 2000;69:308-312.
97. Isacson D, Bingefors K, Kristiansen IS, Nyholm D. Fluctuating functions related to quality of life in advanced Parkinson disease: effects of duodenal levodopa infusion. Acta Neurol Scand 2008;118:379-386.
98. Pohar SL, Allyson Jones C. The burden of Parkinson disease (PD) and concomitant comorbidities. Arch Gerontol Geriatr 2009;49:317-321.
99. Jones CA, Pohar SL, Patten SB. Major depression and health-related quality of life in Parkinson's disease. Gen Hosp Psychiatry 2009;31:334-340.